Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy.

Conclusions: All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival. PMID: 30301310 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30301310?dopt=Abstract

Source: The Korean Journal of Internal Medicine - October 12, 2018 Category: Internal Medicine Authors: Lee IH, Kang BW, Kim JG, Bae WK, Ki MS, Park I, Jo JC, Kim JY, Koh SA, Lee KH, Cho YY, Ryoo HM, Kwak SG, Lee JL, Lee SA Tags: Korean J Intern Med Source Type: research